SCHEMBL2639486

SCHEMBL2639486

O=[C]CN1C(=O)C=CC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 11/20 0.50
FAAH O00519 4/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
BLM P54132 2/20 0.50
GMNN O75496 1/20 0.50
THPO P40225 1/20 0.50
PMP22 Q01453 1/20 0.50
HPGD P15428 2/20 0.48
HSP90AA1 P07900 1/20 0.48
TLR9 Q9NR96 1/20 0.48
TP53 P04637 1/20 0.48
PKM P14618 1/20 0.48
XBP1 P17861 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
RECQL P46063 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10699322 0.78 MGLL (0.46) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL379033 0.78 MAOA (0.47) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL34594 0.76 MGLL (0.56) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL17070868 0.74 MGLL (0.48) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL366266 0.72 MGLL (0.65) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14678413 0.71 MGLL (0.77) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL114195 0.71 MGLL (0.58) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL145737 0.71 MGLL (0.77) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL19514746 0.71 MGLL (0.70) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL278150 0.71 CHRM2 (0.52) MGLLFAAHALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257606-A1 PREPARATION AND USE OF ANTI-FSHR ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF Canwell (GZ) Biotech Limited (CN) 2023-10-11 EP claimed
CN-114605542-A anti-FSHR antibody, preparation method and application of antibody-drug conjugate thereof 康威(广州)生物科技有限公司 2022-06-10 CN claimed
CN-110643032-B Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2022-01-28 CN claimed
CN-110643032-A Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2020-01-03 CN claimed
JP-4732331-B2 2011-07-27 JP claimed
US-7521531-B2 Methods for the purification of stable radioiodine conjugates IMMUNOMEDICS, INC. (US) 2009-04-21 US claimed
EP-1592476-B1 METHODS FOR THE PURIFICATION OF STABLE RADIOIODINE CONJUGATES IMMUNOMEDICS INC (US) 2007-04-11 EP claimed
EP-1592476-A1 METHODS FOR THE PURIFICATION OF STABLE RADIOIODINE CONJUGATES Immunomedics, Inc. (US) 2005-11-09 EP claimed
US-6858705-B2 Stable radioiodine conjugates and methods for their synthesis IMMUNOMEDICS, INC. (US) 2005-02-22 US claimed
US-6818742-B1 FOR IN VIVO RADIOIMMUNODETECTION/DIAGNOSIS/THERAPY OF CANCER/TUMORS IMMUNOMEDICS, INC. 2004-11-16 US claimed
WO-2004071571-A1 METHODS FOR THE PURIFICATION OF STABLE RADIOIODINE CONJUGATES IMMUNOMEDICS, INC. (US) 2004-08-26 WO claimed
US-20040086454-A1 Stable radioiodine conjugates and methods for their synthesis IMMUNOMEDICS, INC. 2004-05-06 US claimed
US-20030220470-A1 Methods for the purification of stable radioiodine conjugates IMMUNOMEDICS, INC. 2003-11-27 US claimed
CN-118105511-A Antibody coupling drug and preparation method and application thereof 浙江大学 2024-05-31 CN disclosed
US-20240115648-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES SEAGEN INC (US) 2024-04-11 US disclosed
US-20240043548-A1 PREPARATION AND USE OF ANTI-FSHR ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF CANWELL (GZ) BIOTECH LIMITED (CN) 2024-02-08 US disclosed
US-6858705-B2 Stable radioiodine conjugates and methods for their synthesis IMMUNOMEDICS, INC. (US) 2005-02-22 US disclosed
US-6818742-B1 FOR IN VIVO RADIOIMMUNODETECTION/DIAGNOSIS/THERAPY OF CANCER/TUMORS IMMUNOMEDICS, INC. 2004-11-16 US disclosed
US-20040086454-A1 Stable radioiodine conjugates and methods for their synthesis IMMUNOMEDICS, INC. 2004-05-06 US disclosed
US-4560648-A CONJUGATED THROUGH THIO GROUP OF B-GALACTOSIDASE SYNTEX (U.S.A.) INC. (US) 1985-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043548-A1 PREPARATION AND USE OF ANTI-FSHR ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF FSHR, GNRHR, SHBG MGLL 4804/4885FAAH 2177/4885ALDH1A1 4414/4885
US-20240115648-A1 HYDROPHILIC ANTIBODY-DRUG CONJUGATES CD44, FCGR1A, FCGR2A MGLL 3217/4885FAAH 1248/4885ALDH1A1 535/4885
US-20040086454-A1 Stable radioiodine conjugates and methods for their synthesis PTMS, DNPEP, ANPEP MGLL 3249/4885FAAH 2426/4885ALDH1A1 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.